André P. Fay - Publications, H-index & Citations

André P. Fay

Hospital Nora Teixeira and PUC RS School of Medicine

33H指数

255论文数

6.4K被引数

收录论文 54

发表时间

Corrigendum to Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study [European Journal of Cancer Volume 213, December 2024, 115078]勘误：Talazoparib 联合 enzalutamide 治疗 metastatic castration-resistant prostate cancer 的安全性分析，来自随机、安慰剂对照、III 期 TALAPRO-2 研究的结果 [European Journal of Cancer Volume 213, December 2024, 115078]

European Journal of Cancer

IF7.1

2025-11-13

PREAI

Arun A. Azad; Karim Fizazi; Nobuaki Matsubara; Fred Saad; Ugo De Giorgi; Jae Young Joung; Peter C.C. Fong; Robert J. Jones; Stefanie Zschäbitz; Jan Oldenburg; Neal D. Shore; Curtis Dunshee; Joan Carles; Andre P. Fay; Xun Lin; Liza DeAnnuntis; Nicola Di Santo; Michael A. Zielinski; Neeraj Agarwal

Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 Phase III study Capivasertib 联合 Abiraterone 治疗 PTEN 缺失的转移性激素敏感性前列腺癌：CAPItello-281 III 期研究

Annals of Oncology

IF65.4

2025-10-19

OAAI

Karim Fizazi; Noel W. Clarke; Maria De Santis; Hirotsugu Uemura; Andre P. Fay; Nuri Karadurmus; Mariusz Kwiatkowski; Carlos Alvarez-Fernandez; Shusuan Jiang; Miguel Sotelo; Dominique Parslow; Niara Oliveira; Tae Gyun Kwon; Dingwei Ye; Steve Boudewijns; Pongwut Danchaivijitr; Claire Rooney; Christopher Gresty; Marc Yeste-Velasco; Jill Logan; Daniel J. George

Immune-based Combinations in Intermediate-/Poor-risk Patients with Non–clear Cell Renal Cell Carcinoma: Results from the ARON-1 Study 基于免疫的组合疗法在非透明细胞肾细胞癌中/高风险患者中的应用：ARON-1研究的结果

European Urology Focus

IF5.6

2025-07-29

PREAI

Francesco Massari; Veronica Mollica; Ray Manneh Kopp; Enrique Grande; Ondřej Fiala; Ravindran Kanesvaran; Haoran Li; Timothy J. Schieber; Maria José Juan Fita; Alexandr Poprach; Cristian Lolli; Maria T. Bourlon; Alfonso Gómez de Liaño; Francesco Grillone; Kaisa Sunela; Alessandro Rizzo; Marwan Ghosn; Linda Cerbone; Tarek Taha; Yüksel Ürün; Javier Molina-Cerrillo; Teresa Alonso-Gordoa; Edoardo Lenci; Inmaculada Orejana Martin; Hussam Abu-Sini; Pasquale Rescigno; Dipen Bhuva; Andre Poisl Fay; Vincenza Conteduca; Ahmet Yildirim; Matteo Rosellini; Umut Akova; Elisa Tassinari; Hatice Bölek; Andrey Soares; Fernando Sabino Marques Monteiro; Sebastiano Buti; Mehmet Asim Bilen; Matteo Santoni

Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial Talazoparib 联合 enzalutamide 治疗 metastatic castration-resistant prostate cancer 男性患者的最终总生存结果：来自随机、安慰剂对照、III期 TALAPRO-2 试验的数据

lancet

IF0

2025-07-16

PREAI

Neeraj Agarwal; Arun A Azad; Joan Carles; André P Fay; Nobuaki Matsubara; Cezary Szczylik; Ugo De Giorgi; Jae Young Joung; Peter C C Fong; Eric Voog; Robert J Jones; Neal D Shore; Fred Saad; Curtis Dunshee; Stefanie Zschäbitz; Jan Oldenburg; Xun Lin; Cynthia G Healy; Matko Kalac; Dana Kennedy; Karim Fizazi

Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial Talazoparib 联合 enzalutamide 治疗 HRR 缺陷型转移性去势抵抗性前列腺癌的男性患者：来自随机、安慰剂对照的 III 期 TALAPRO-2 试验的最终总生存结果

lancet

IF0

2025-07-16

PREAI

Karim Fizazi; Arun A Azad; Nobuaki Matsubara; Joan Carles; André P Fay; Ugo De Giorgi; Jae Young Joung; Peter C C Fong; Eric Voog; Robert J Jones; Neal D Shore; Curtis Dunshee; Stefanie Zschäbitz; Jan Oldenburg; Dingwei Ye; Xun Lin; Matko Kalac; A Douglas Laird; Dana Kennedy; Neeraj Agarwal

Germline Genetic Testing in Breast Cancer: Utilization and Disparities in a Middle-Income Country

JCO GLOBAL ONCOLOGY

IF3

2025-03-01

OAAI

de Souza, Alessandra Borba Anton; Barrios, Carlos; de Jesus, Rafaela Gomes; Reinert, Tomas; Giacomazzi, Juliana; Rosa, Daniela D.; Cronemberger, Eduardo; Werutsky, Gustavo; Bines, Jose; Queiroz, Geraldo Silva; de Lima, Vladmir Cordeiro; Freitas-Junior, Ruffo; Couto Filho, Jose d'Oliveira; Emerenciano, Karla; Resende, Heloisa; Crocamo, Susanne; Van Eyll, Brigitte; Neron, Yeni; Dybal, Vanessa; Lazaretti, Nicolas Silva; Costamilan, Rita de Cassia; de Andrade, Diocesio Alves Pinto; Mathias, Clarissa; Vacaro, Giovana Zerwes; Borges, Giuliano; Morelle, Alessandra Menezes; Sampaio Filho, Carlos Alberto; Mano, Max; Lichtenfels, Martina; Simon, Sergio D.; Fay, Andre P.

Androgen Receptor Pathway Inhibitor Therapy for Advanced Prostate Cancer 雄激素受体通路抑制剂疗法用于晚期前列腺癌

JAMA NETWORK OPEN

IF9.7

2025-01-13

OAAI

Bastos, Diogo Assed; Soares, Andrey; Schutz, Fabio Augusto Barros; Cronemberger, Eduardo; de Almeida Luz, Murilo; Martins, Suelen Patricia Dos Santos; Muniz, David Queiroz Borges; Carcano, Flavio Mavignier; Smaletz, Oren; Peixoto, Fabio Affonso; Gomes, Andrea Juliana; Cruz, Felipe Melo; Franke, Fabio Andre; Herchenhorn, Daniel; Gidekel, Rosemarie; Werutsky, Gustavo; Rebelatto, Taiane Francieli; Gomes de Jesus, Rafaela; Souza, Vinicius Carrera; Fay, Andre Poisl; Maluf, Fernando Cotait

Prediction of the probability of metastasis to the sentinel lymph node in breast cancer by ATR-FTIR spectroscopy and chemometrics 通过ATR-FTIR光谱技术和化学计量学预测乳腺癌向哨兵淋巴结转移的概率

VIBRATIONAL SPECTROSCOPY

IF3.1

2025-01-01

PREAI

de Souza, Nikolas Mateus Pereira; da Rosa, Dhuli Kimberli Abeg; de Moraes, Caroline; Padoin, Licerio Vicente; Pra, Daniel; Fay, Andre Poisl; Corbellini, Valeriano Antonio

Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study Talazoparib联合enzalutamide治疗转移性去势抵抗性前列腺癌: 来自随机，安慰剂对照，III期TALAPRO-2研究的安全性分析

EUROPEAN JOURNAL OF CANCER

IF7.1

2024-12-01

OAAI

Azad, Arun A.; Fizazi, Karim; Matsubara, Nobuaki; Saad, Fred; De Giorgi, Ugo; Joung, Jae Young; Fong, Peter C. C.; Jones, Robert J.; Zschaebitz, Stefanie; Oldenburg, Jan; Shore, Neal D.; Dunshee, Curtis; Carles, Joan; Fay, Andre P.; Lin, Xun; Deannuntis, Liza; Di Santo, Nicola; Zielinski, Michael A.; Agarwal, Neeraj

Efficacy of talazoparib and enzalutamide in mCRPC patients previously treated with androgen receptor pathway inhibitors (ARPI) or docetaxel: Post hoc analysis from both cohorts in TALAPRO-2 study talazoparib和enzalutamide在先前接受过雄激素受体通路抑制剂（ARPI）或多西他赛的mCRPC患者中的疗效：来自TALAPRO-2研究两个队列的事后分析

ANNALS OF ONCOLOGY

IF65.4

2024-09-01

PREAI

Agarwal, N.; Azad, A. A.; Galceran, J. C.; Fay, A. P.; Matsubara, N.; Szczylik, C.; De Giorgi, U.; Joung, J. Y.; Fong, P. C.; Voog, E.; Jones, R. J.; Shore, N. D.; Dunshee, C.; Zschaebitz, S.; Oldenburg, J.; Lin, X.; Laird, D.; Kalac, M.; Kennedy, D.; Fizazi, K.

Incidence of hematologic toxicities in the homologous recombination repair (HRR)-deficient population of the TALAPRO-2 trial and their potential association with germline vs somatic origin of HRR gene alterations 同源重组修复（HRR）缺陷人群中TALAPRO-2试验的血液学毒性发生率及其与HRR基因改变生殖系来源与体细胞来源的潜在关联

ANNALS OF ONCOLOGY

IF65.4

2024-09-01

PREAI

Azad, A. A.; Agarwal, N.; Shore, N. D.; Galceran, J. C.; Fay, A. P.; Matsubara, N.; Saad, F.; De Giorgi, U.; Joung, J. Y.; Fong, P. C.; Zschaebitz, S.; Piulats Rodriguez, J. M.; Yip, S. M.; Liu, G.; DeAnnuntis, L.; Lin, X.; Laird, D.; Kalac, M.; Fizazi, K.

Plain language summary of the results from the TALAPRO-2 study: Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer TALAPRO-2研究结果的简明语言摘要: 塔拉唑帕利加恩扎鲁他胺与安慰剂加恩扎鲁他胺治疗晚期前列腺癌的比较

FUTURE ONCOLOGY

IF2.6

2024-07-12

OAAI

Agarwal, Neeraj; Azad, Arun A.; Carles, Joan; Fay, Andre P.; Matsubara, Nobuaki; Heinrich, Daniel; Szczylik, Cezary; Giorgi, Ugo De; Joung, Jae Young; Fong, Peter C.; Voog, Eric; Jones, Robert J.; Shore, Neal D.; Dunshee, Curtis; Zschabitz, Stefanie; Oldenburg, Jan; Lin, Xun; Healy, Cynthia G.; Di Santo, Nicola; Zohren, Fabian; Fizazi, Karim

TMPRSS2-ERG and RB1 as candidate predictive biomarkers for efficacy in TALAPRO-2: Phase 3 study of talazoparib (TALA) plus enzalutamide (ENZA) vs placebo (PBO) plus ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

CANCER RESEARCH

IF16.6

2024-04-05

PREAI

Piulats, Josep M.; Azad, Arun A.; Laird, A. Douglas; Matsubara, Nobuaki; Fizazi, Karim; Shore, Neal D.; Karsh, Lawrence; Liu, Glenn; Fay, Andre P.; Carles, Joan; Jones, Robert J.; Voog, Eric; Zschabitz, Stefanie; De Giorgi, Ugo; Yip, Steven M.; Mu, Xinmeng Jasmine; Lin, Xun; Engelsberg, Arne; Agarwal, Neeraj

Identification of a novel agnostic predictive multiomic signature via Elastic Net/Machine Learning in TALAPRO-2 ( TP-2), a phase 3 study of talazoparib (TALA) plus enzalutamide (ENZA) vs placebo (PBO) plus ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

CANCER RESEARCH

IF16.6

2024-04-05

PREAI

Liu, Glenn; Mu, Xinmeng Jasmine; Fizazi, Karim; Laird, A. Douglas; Matsubara, Nobuaki; Yip, Steven M.; Pu, Jie; Carles, Joan; Fay, Andre P.; Jones, Robert J.; Zschaebitz, Stefanie; Piulats, Josep M.; Joung, Jae Young; Roh, Whijae; Chelliserry, Jijumon; Di Santo, Nicola; Saul, Michelle; Azad, Arun A.; Agarwal, Neeraj

First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial (vol 30, pg 257, 2024)一线talazoparib联合恩扎鲁他胺治疗HRR缺乏的转移性去势抵抗性前列腺癌: 3期TALAPRO-2试验 (第30卷，257页，2024页)

NATURE MEDICINE

IF50

2024-01-31

OAAI

Fizazi, Karim; Azad, Arun A.; Matsubara, Nobuaki; Carles, Joan; Fay, Andre P.; De Giorgi, Ugo; Joung, Jae Young; Fong, Peter C. C.; Voog, Eric; Jones, Robert J.; Shore, Neal D.; Dunshee, Curtis; Zschabitz, Stefanie; Oldenburg, Jan; Ye, Dingwei; Lin, Xun; Healy, Cynthia G.; Di Santo, Nicola; Laird, A. Douglas; Zohren, Fabian; Agarwal, Neeraj

Marital Status, Living Arrangement, and Survival among Individuals with Advanced Prostate Cancer in the International Registry for Men with Advanced Prostate Cancer

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

IF3.4

2024-01-08

OAAI

Chen, Naiyu; Mcgrath, Colleen B.; Ericsson, Caroline I.; Vaselkiv, Jane B.; Rencsok, Emily M.; Stopsack, Konrad H.; Guard, Hannah E.; Autio, Karen A.; Rathkopf, Dana E.; Enting, Deborah; Bitting, Rhonda L.; Mateo, Joaquin; Githiaka, Charles W.; Chi, Kim N.; Cheng, Heather H.; Davis, Ian D.; Anderson, Simon G.; Badal, Simone Ann Marie; Bjartell, Anders; Russnes, Kjell M.; Heath, Elisabeth I.; Pomerantz, Mark M.; Henegan, John C.; Hyslop, Terry; Esteban, Emilio; Omlin, Aurelius; Mcdermott, Ray; Fay, Andre P.; Popoola, Ademola Alabi; Ragin, Camille; Nowak, Joel; Gerke, Travis; Kantoff, Philip W.; George, Daniel J.; Penney, Kathryn L.; Mucci, Lorelei A.

First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial 一线talazoparib联合恩扎鲁他胺治疗HRR缺乏的转移性去势抵抗性前列腺癌: 3期TALAPRO-2试验

NATURE MEDICINE

IF50

2023-12-04

OAAI

Fizazi, Karim; Azad, Arun A.; Matsubara, Nobuaki; Carles, Joan; Fay, Andre P.; De Giorgi, Ugo; Joung, Jae Young; Fong, Peter C. C.; Voog, Eric; Jones, Robert J.; Shore, Neal D.; Dunshee, Curtis; Zschaebitz, Stefanie; Oldenburg, Jan; Ye, Dingwei; Lin, Xun; Healy, Cynthia G.; Di Santo, Nicola; Laird, A. Douglas; Zohren, Fabian; Agarwal, Neeraj

Talazoparib (TALA) plus enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC): Subgroup analyses of the all-comers cohort from TALAPRO-2 by homologous recombination repair (HRR) status Talazoparib (TALA) 加恩扎鲁他胺 (ENZA) 治疗转移性去势抵抗性前列腺癌 (mCRPC): 通过同源重组修复 (HRR) 状态对来自TALAPRO-2的所有参与者队列进行亚组分析

ANNALS OF ONCOLOGY

IF65.4

2023-10-01

OAAI

Matsubara, N.; Fizazi, K.; Azad, A. A.; Galceran, J. Carles; Fay, A. P.; De Giorgi, U. F. F.; Joung, J. Y.; Fong, P. C.; Voog, E.; Jones, R. J.; Shore, N. D.; Dunshee, C.; Zschaebitz, S.; Karsh, L. I.; Barthelemy, P.; Lin, X.; Healy, C. G.; Di Santo, N.; Zohren, F.; Agarwal, N.

Patient-reported outcomes (PROs) in men with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) mutations receiving talazoparib (TALA) plus enzalutamide (ENZA) vs placebo (PBO) plus ENZA: Results from a phase III (TALAPRO-2) study 接受talazoparib (TALA) 加恩扎鲁他胺 (ENZA) 与安慰剂 (PBO) 加ENZA的转移性去势抵抗性前列腺癌 (mCRPC) 和同源重组修复 (HRR) 突变男性的患者报告结局 (PROs): III期 (TALAPRO-2) 研究的结果

ANNALS OF ONCOLOGY

IF65.4

2023-10-01

OAAI

Fay, A. P.; Fizazi, K.; Matsubara, N.; Azad, A. A.; Saad, F.; De Giorgi, U. F. F.; Joung, J. Y.; Fong, P. C.; Jones, R. J.; Zschaebitz, S.; Oldenburg, J.; Shore, N. D.; Dunshee, C.; Galceran, J. Carles; Cislo, P.; Chang, J.; Healy, C. G.; Niyazov, A.; Agarwal, N.

Exploration of germline (g) vs somatic (s) origin of homologous recombination repair (HRR) gene alterations and potential associations with antitumor activity in the HRR-deficient population from TALAPRO-2 同源重组修复 (HRR) 基因改变的种系 (g) 与体细胞 (s) 起源的探索以及与TALAPRO-2 HRR缺陷人群中抗肿瘤活性的潜在关联

ANNALS OF ONCOLOGY

IF65.4

2023-10-01

PREAI

Yip, S. M.; Fizazi, K.; Matsubara, N.; Azad, A. A.; Joung, J. Y.; Fong, P. C.; Galceran, J. Carles; De Giorgi, U. F. F.; Jones, R. J.; Liu, G.; Fay, A. P.; Voog, E.; Zschaebitz, S.; Oldenburg, J.; Di Santo, N.; Healy, C. G.; Lin, X.; Laird, D.; Agarwal, N.

研究方向